Healthcare Market Dynamics
Expert articles and analysis related to healthcare market dynamics.
AI Summary — Last 30 Days
Medicare risk is becoming more concentrated and analytics-dependent: geographically dispersed, high-earning ACOs backed by third-party conveners are expanding the MSSP playbook, while vendors are moving quickly to help organizations model downside exposure under CMS’s LEAD ACO program (Health Affairs, [Arbital Health ATLAS](
Related Articles
STAT+: Trump’s drug-pricing deals set to be tested by new product launches
The public is about to get its first look at the prices of drugs launched since President Trump struck his most-favored-nation deals with 17 drugmakers.
Opinion: The innovation trap: How pharma weaponizes a word to extend monopolies
“Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this excerpt from “Pharma Monopoly.”
When Cost-Effectiveness Thresholds Drift: Global HTA, MFN Pricing, And The Need For A Coherent Framework
When Cost-Effectiveness Thresholds Drift: Global HTA, MFN Pricing, And The Need For A Coherent Framework Health Affairs
Manufacturer-Sponsored Coupon Use and Brand-Name Drug Costs Among Patients With Insurance
Manufacturer-Sponsored Coupon Use and Brand-Name Drug Costs Among Patients With Insurance JAMA
340B lawsuits against CVS allege $250M in underpaid hospital reimbursement
CVS Health’s pharmacy benefit manager (PBM) under-reimbursed three health systems by almost $250 million over five years in connection with the 340B Drug Pricing Program, according to new lawsuits. Fi...
Would lowering ANDA costs boost domestic generic drug production?
Mark Cuban recently told Healthcare Brew the costs “kill the economics” for drugmakers like his.
Specialty Pharmacy, Explained: Growth, Pricing and Industry Economics
CVS sues to challenge Tennessee's new PBM law
CVS sues to challenge Tennessee's new PBM law Fierce Healthcare